Literature DB >> 7803250

High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis.

N J Beauchamp1, M E Daly, K K Hampton, P C Cooper, F E Preston, I R Peake.   

Abstract

Recent findings have indicated the importance of factor V (FV) in causing resistance to activated protein C (APC) in a high proportion of patients with venous thrombosis. This prompted us to investigate whether resistance could be due to defective inactivation of FVa by APC. Consequently, we amplified a 3.2 kb fragment of the FV gene sequence encoding the heavy chain APC cleavage site. DNA analysis showed a guanine to adenine transition at nucleotide 1691 in all affected members of two families with inherited APC resistance associated with thrombosis and confirmed suspected homozygosity in two individuals. The mutation, in heterozygous form, was also found in approximately 3.5% of our normal population (n = 144) and correlated with low APC resistance. The high prevalence of this mutation suggests that it may be a major contributory factor in early thrombosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803250     DOI: 10.1111/j.1365-2141.1994.tb05005.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Postmortem diagnosis of Factor V Leiden from paraffin wax embedded tissue.

Authors:  J S Webb; G R Standen; C M Collins; C P Case
Journal:  Clin Mol Pathol       Date:  1996-06

2.  An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.

Authors:  B Clark; C Caine; E N McSweeney; B A McVerry; H C Gooi
Journal:  Clin Mol Pathol       Date:  1996-08

3.  Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.

Authors:  A Ferreira-Gonzalez; L M Fisher; C M Lehman; M H Langley; D H Lofland; Q Xia; N X Nguyen; D Modesto; J B Willoughby; D S Wilkinson; C T Garrett
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

4.  Activated protein C and retinal vein occlusion.

Authors:  B J Hunt
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

5.  Evaluation of chromosomal abnormalities and common trombophilic mutations in cases with recurrent miscarriage.

Authors:  Ahmet Karatas; Recep Eroz; Mustafa Albayrak; Tulay Ozlu; Bulent Cakmak; Fatih Keskin
Journal:  Afr Health Sci       Date:  2014-03       Impact factor: 0.927

6.  Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.

Authors:  J D Cavenagh; B T Colvin
Journal:  Postgrad Med J       Date:  1996-02       Impact factor: 2.401

7.  Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.

Authors:  W Prohaska; H Mannebach; M Schmidt; U Gleichmann; K Kleesiek
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

8.  Amplification of PCR products in excess of 600 base pairs using DNA extracted from decalcified, paraffin wax embedded bone marrow trephine biopsies.

Authors:  C L Wickham; M Boyce; M V Joyner; P Sarsfield; B S Wilkins; D B Jones; S Ellard
Journal:  Mol Pathol       Date:  2000-02

9.  Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis.

Authors:  A E Mahmoud; E Elias; N Beauchamp; J T Wilde
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

10.  Prevalence of factor V Leiden in a Canadian blood donor population.

Authors:  D H Lee; P A Henderson; M A Blajchman
Journal:  CMAJ       Date:  1996-08-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.